Global Payoneer (NASDAQ: PAYO – Get a rating) and molecular data (NASDAQ: MKD – Get a rating) are both small-cap business services companies, but which stock is superior? We’ll compare the two companies based on their risk strength, earnings, dividends, analyst recommendations, institutional ownership, valuation, and profitability.
Profitability
This table compares the net margins, return on equity, and return on assets of Payoneer Global and Molecular Data.
Net margins | Return on equity | return on assets | |
Global Payoneer | -2.01% | -14.21% | -1.48% |
Molecular data | N / A | N / A | N / A |
Institutional and insider ownership
66.3% of Payoneer Global shares are held by institutional investors. By comparison, 42.9% of Molecular Data’s shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers, and hedge funds believe a company is poised for long-term growth.
Analyst Notes
This is a breakdown of current ratings and price targets for Payoneer Global and Molecular Data, as provided by MarketBeat.com.
Sales Ratings | Hold odds | Buy reviews | Strong buy odds | Rating | |
Global Payoneer | 0 | 1 | 5 | 0 | 2.83 |
Molecular data | 0 | 0 | 0 | 0 | N / A |
Payoneer Global currently has a consensus target price of $10.33, indicating a potential upside of 102.61%. Considering Payoneer Global’s possible higher upside, research analysts clearly believe that Payoneer Global is more favorable than Molecular Data.
Volatility and risk
Payoneer Global has a beta of 0.64, which means its stock price is 36% less volatile than the S&P 500. By comparison, Molecular Data has a beta of 1.08, which means its stock price is 8% more volatile than the S&P 500.
Benefits and evaluation
This chart compares revenue, earnings per share, and valuation of Payoneer Global and Molecular Data.
Gross revenue | Price/sales ratio | Net revenue | Earnings per share | Price/earnings ratio | |
Global Payoneer | $473.40 million | 3.68 | -$33.95 million | ($0.63) | -8.10 |
Molecular data | $1.16 billion | 0.01 | -$50.27 million | N / A | N / A |
Payoneer Global has higher revenue, but lower revenue than Molecular Data.
About Payoneer Global (Get a rating)
Payoneer Global Inc. operates a payment and commerce platform that facilitates online marketplaces, platforms and merchants worldwide. It offers a suite of services that includes cross-border payments, B2B accounts payable/receivable, multi-currency accounts, physical and virtual Mastercard, working capital, merchant, tax, compliance and risk, and more. The company’s platform offers bank-grade security, stability and redundancy combined with modern digital capabilities that interconnect the world on a single platform. Its cross-border payment solutions support an ecosystem of marketplaces and marketplace sellers to pay their sellers in approximately 190 countries and territories by connecting to Payoneer APIs and for sellers to get paid. The company was founded in 2005 and is based in New York, New York.
About Molecular Data (Get a rating)
Molecular Data Inc., through its subsidiaries, operates in the chemical e-commerce business in the People’s Republic of China. The company operates a technology-driven platform that connects participants across the chemical value chain through its integrated solutions. It provides e-commerce solutions, financial solutions, warehousing and logistics solutions, and software-as-a-service suites for traditional chemical industry participants. The Company offers its e-commerce solutions through an online platform consisting of molbase.com and molbase.cn websites; Moku Data Weixin account; chemical community application; and other auxiliary platforms. Molecular Data Inc. was founded in 2013 and is headquartered in Shanghai, People’s Republic of China.
Get news and reviews for Payoneer Global Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Payoneer Global and related companies with MarketBeat.com’s free daily email newsletter.